Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.

abstract：BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4)...

journal_title：Clinical neuropharmacology

authors： Rissardo JP,Caprara ALF

更新日期：2020-07-01 00:00:00

abstract：:Transient global amnesia (TGA) has been proposed as a possible adverse effect of sildenafil. There are rare cases in the literature, but none had strong evidence to support. Our case is the first to demonstrate a focal punctate diffusion-weighted imaging lesion at the right hippocampus after the use of sildenafil. Thi...

journal_title：Clinical neuropharmacology

authors： Lin KY,Liu MN,Wang PH,Lau CI

更新日期：2020-03-01 00:00:00

abstract：:Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...

journal_title：Clinical neuropharmacology

authors： Huang CC,Shiah IS,Chen HK,Mao WC,Yeh YW

更新日期：2008-07-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：:We assessed in 15 consecutive patients the best route and time of administration for phenytoin (PHT) prophylaxis in neurosurgical procedures. We also correlated PHT levels in serum and cerebrospinal fluid after oral and parenteral loading doses. The mean PHT level was 13.9 micrograms/ml in serum and 2.03 micrograms/ml...

journal_title：Clinical neuropharmacology

authors： Rabinowicz AL,Salvat JM,Leiguarda RC,Demonty F,Salvat F,Cervio A,Manes F,Lazarowski A

更新日期：1997-10-01 00:00:00

abstract：:Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

journal_title：Clinical neuropharmacology

authors： Rajput AH,Rozdilsky B,Rajput A,Ang L

更新日期：1990-12-01 00:00:00

abstract：:Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...

journal_title：Clinical neuropharmacology

authors： Hasegawa H,Kanner AM

更新日期：1995-02-01 00:00:00

abstract：:Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

journal_title：Clinical neuropharmacology

authors： Schachter SC

更新日期：1999-11-01 00:00:00

abstract：:Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA...

journal_title：Clinical neuropharmacology

authors： Strous RD,Maayan R,Kotler M,Weizman A

更新日期：2005-11-01 00:00:00

abstract：:To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

journal_title：Clinical neuropharmacology

authors： Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

更新日期：2000-01-01 00:00:00

abstract：:A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

journal_title：Clinical neuropharmacology

authors： Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

更新日期：1983-01-01 00:00:00

abstract：OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

journal_title：Clinical neuropharmacology

authors： López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

更新日期：2006-07-01 00:00:00

abstract：:This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

journal_title：Clinical neuropharmacology

authors： Kemali D

更新日期：1989-01-01 00:00:00

abstract：:The effects of 5-HT are varied and widely distributed throughout the human body. At this time, 5-HT research is a field ripe for "plucking." Not only is there a great demand for more selective agonists and antagonists, but there is more than enough work needed in receptor binding studies to keep pharmacologists employ...

journal_title：Clinical neuropharmacology

authors： Bonate PL

更新日期：1991-02-01 00:00:00

abstract：OBJECTIVE:Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS:Electroneurographic assessments with surface electrodes were performed aft...

journal_title：Clinical neuropharmacology

authors： Wohlfarth K,Müller C,Sassin I,Comes G,Grafe S

更新日期：2007-03-01 00:00:00

abstract：:Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...

journal_title：Clinical neuropharmacology

authors： Micheli F,Gatto M,Lekhuniec E,Mangone C,Fernandez Pardal M,Pikielny R,Casas Parera I

更新日期：1990-02-01 00:00:00

abstract：:The mortality risk associated with cardiovascular disease is significantly increased in patients with major depression and panic disorder. The mechanism of this phenomenon is unclear. Thrombin is responsible for platelet aggregation and shape change, and it plays a significant role in the development of thromboembolic...

journal_title：Clinical neuropharmacology

authors： Berk M,Plein H

更新日期：2000-07-01 00:00:00

abstract：RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory ep...

journal_title：Clinical neuropharmacology

authors： Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

更新日期：2008-11-01 00:00:00

abstract：:Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

journal_title：Clinical neuropharmacology

authors： Gagiano CA,Hart GA,Bodemer W,Schall R

更新日期：1994-01-01 00:00:00

abstract：:Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consist...

journal_title：Clinical neuropharmacology

authors： Colosimo C,Merello M,Albanese A

更新日期：1994-06-01 00:00:00

abstract：:The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

更新日期：1994-02-01 00:00:00

abstract：:Trazodone is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of depression and insomnia. Fatal overdose is rare and usually occurs when combined with other drugs or alcohol. Only a few lethal cases of pure trazodone overdose have been reported, all attributed to cardiotoxicity. We r...

journal_title：Clinical neuropharmacology

authors： Avila JD

更新日期：2017-09-01 00:00:00

abstract：:Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

更新日期：1996-04-01 00:00:00

abstract：:A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

journal_title：Clinical neuropharmacology

authors： Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

更新日期：1987-08-01 00:00:00

abstract：:Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targe...

journal_title：Clinical neuropharmacology

authors： Schuster NM,Rapoport AM

更新日期：2017-07-01 00:00:00

abstract：:The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

journal_title：Clinical neuropharmacology

authors： Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

更新日期：2000-03-01 00:00:00

abstract：:Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...

journal_title：Clinical neuropharmacology

authors： Richard IH,Justus AW,Greig NH,Marshall F,Kurlan R

更新日期：2002-11-01 00:00:00

abstract：OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

journal_title：Clinical neuropharmacology

authors： Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

更新日期：2017-11-01 00:00:00

abstract：:Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

journal_title：Clinical neuropharmacology

authors： Brindley DN

更新日期：1988-01-01 00:00:00

abstract：OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pat...

journal_title：Clinical neuropharmacology

authors： Urbano M,Okwara L,Manser P,Hartmann K,Herndon A,Deutsch SI

更新日期：2014-05-01 00:00:00